Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665229 | 0.82 | DAO (0.58) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| SCHEMBL1423671 | 0.81 | KMT2A (0.54) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| SCHEMBL1007015 | 0.81 | MAPK1 (0.61) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| SCHEMBL163302 | 0.81 | KMT2A (0.54) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| SCHEMBL28513498 | 0.81 | NPSR1 (0.41) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| SCHEMBL23013382 | 0.80 | MAPK1 (0.65) | L3MBTL1NPSR1KMT2APOLBALPL | |
| SCHEMBL13369577 | 0.80 | NPSR1 (0.52) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| SCHEMBL930612 | 0.79 | KMT2A (0.52) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| SCHEMBL17593217 | 0.79 | KMT2A (0.52) | L3MBTL1NPSR1KMT2APOLBTHRB | |
| Ethane SCHEMBL6614658 | 0.79 | MAPK1 (0.59) | L3MBTL1NPSR1KMT2APOLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3668881-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111032046-B | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-3668512-B1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-11464775-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3668881-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668512-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111032046-A | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035863-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | L3MBTL1 1203/4885NPSR1 3584/4885KMT2A 701/4885 |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | PDK1, PDK2, PDK4 | L3MBTL1 1203/4885NPSR1 3584/4885KMT2A 701/4885 |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | L3MBTL1 774/4885NPSR1 3219/4885KMT2A 578/4885 |
| US-11464775-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | L3MBTL1 1203/4885NPSR1 3584/4885KMT2A 701/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | L3MBTL1 774/4885NPSR1 3219/4885KMT2A 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.